Singapore markets closed
Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,018.79 +0.40 (+0.01%) Dow
37,954.41 +51.12 (+0.13%) Nasdaq
15,634.53 +29.05 (+0.19%) Bitcoin USD
58,650.54 +1,247.27 (+2.17%) CMC Crypto 200
1,260.50 -10.24 (-0.81%)
Regeneron Pharmaceuticals, Inc. (0R2M.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
As of 02:42PM BST. Market open.
| Previous close | 897.37 |
| Open | 905.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 897.58 - 919.07 |
| 52-week range | 689.00 - 998.57 |
| Volume | |
| Avg. volume | 1,962 |
| Market cap | 1.013B |
| Beta (5Y monthly) | 0.14 |
| PE ratio (TTM) | 0.13 |
| EPS (TTM) | 70.31 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GuruFocus.comRegeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenges and Opportunities Amidst ...
First Quarter Results Show Revenue Decline but Strong Dupixent and Libtayo Sales Growth
Simply Wall St.Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock...
GlobeNewswireRegeneron Reports First Quarter 2024 Financial and Operating Results
First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first quarter 2023First quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® were $1.40 billion, including $200 million from EYLEA HDFirst quarter 2024 Libtayo® global net sales increased 45% to $264 million versus first quarter 2023First quarter 2024 GAAP dil
© 2024 Yahoo. All rights reserved.